|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only, high-grade malignancy (P < 0.001), lymph node metastasis (P = 0.036) and advanced tumour stage (P = 0.025) are associated with FGFR3 amplification (n = 1) or chromosomal aberrations (low polysomy, n = 61; high polysomy, n = 55) but not with MDM4 alterations.
|
26661925 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genes that encode proteins that regulate p53 function, such as MDM2, MDM4, and CDKN2A (p14(ARF)) are also frequently altered in tumors, and it is generally believed that the p53 pathway is likely to be inactivated by mutation in close to 100% of human tumors.
|
27037420 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As full-length MDM4 is enhanced in multiple human tumors, our data indicate that this strategy is applicable to a wide range of tumor types.
|
26595814 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This induction correlated with reduction in expression of drug resistance genes MDR1, MRP1, ABCG2 and ABCC2 along with decreased expression of PD-L1 which is associated with severe dysfunction of tumor specific CD8<sup>+</sup> T cells.
|
27692344 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
So, it is concluded that Caveolin-1 affects ESCC MDR by regulating the expressions of P-gp and MRP1; therefore, it can be taken as a significant marker and target in tumor therapy.
|
26768616 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MDM2, MDM4 and TP53BP1 polymorphisms were significantly associated with pCR in patients harboring a p53-positive tumor.
|
24958282 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore in a hypomorphic p53(ΔP/ΔP) context, the Mdm4(ΔE6) allele led to p53 activation and delayed the growth of oncogene-induced tumors.
|
25088193 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MDM4 SNP34091C was not associated with risk for any of the tumor forms examined, except for a marginally significant association with reduced risk for breast cancer in a recessive model (OR = 0.77: 95% CI = 0.59-0.99).
|
26471763 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, MDMX ablation leads to significant retardation of xenograft tumor growth, concomitant with RB accumulation.
|
25703327 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p53 pathway regulates stress response, and variations in p53, MDM2, and MDM4 may predispose an individual to tumor development.
|
24625390 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, however, most Rb(+/-) p53(ΔP/ΔP) mice developped pituitary adenomas, but these tumors were rare in Rb(+/-) p53(ΔP/ΔP) Mdm4(-/-) animals, because Mdm4 loss led to increased p21 levels, a suppressor of pituitary tumor growth.
|
23474762 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accumulated evidences demonstrated that oncoprotein MDM4 plays a crucial role in the TP53 tumor suppressor signaling pathway.
|
25203442 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that in epithelial ovarian cancer, MRP1 may be a marker for aggressiveness because its expression was associated with tumor grade and support that MRP4 may play an unfavourable role in disease outcome.
|
24024181 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Verapamil/CDDP co-treatment inhibited tumor xenograft growth via the downregulation of MRP1 expression.
|
23229154 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intriguingly, we observed a unique coordination in the splicing of MDM2-ALT1 and MDM4-ALT2 in approximately 24% of tumor samples in a manner similar to genotoxic stress response in cell lines.
|
24027430 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression level of MDM4-B mRNA detected by real-time PCR was not only significantly associated with tumor stages, but also with p53 mutation and Ki-67 status which are important clinical molecular markers of glioma.
|
23994448 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MDMX is a recently identified MDM2 homolog and its presence in this tumor is unexplored.
|
24018792 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, four recurrent copy number alterations, involving genes that participate to cell growth and cycle, were found to be strongly associated in five tumors not deleted on 1p/19q: gain or amplification at 1q32.1 (MDM4, PIK3C2B genes), 12q14.1 (CDK4 gene), 12q14.3-q15 (MDM2 gene) and homozygous deletion at 22q13.1 (APOBEC3B gene).
|
22825724 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
While mouse double minute (MDM)2 or MDMX protein overexpression (often due to gene amplifications) may inactivate p53 in different tumour forms, so far, there is no evidence for MDM2 amplifications in breast cancers resistant to anthracyclines.
|
22313396 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our study shows that HDACi amplify the antitumor activity of nutlin-3-possibly by inducing p53 hyperacetylation and/or MDM2 and/or MDM4 downregulation-suggesting that treatment with a combination of nutlin-3 and HDACi may be an effective strategy for treating tumors with wild-type p53.
|
20680659 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MDMX binds to p53 and can repress the tumor suppressor function of p53 through inhibiting its trans-activation activity and/or destabilizing the protein.
|
21075910 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene amplification of MDM4 has been identified in a variety of tumors.
|
21503588 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After treatment with the carcinogen dimethylbenzanthracene (DMBA), TP-ras0/+ mice on the Mdm4+/− background developed fewer tumors with a delay in the age of onset of melanomas compared to TP-ras0/+ mice.
|
20849464 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identified an SNP (SNP34091) in the 3'-UTR of MDM4 that creates a putative target site for hsa-miR-191, a microRNA that is highly expressed in normal and tumor tissues.
|
21084273 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, the remaining wild-type p53 allele was retained in most Mdm4(Tg1) p53(+/-) tumors.
|
20736370 |
2010 |